García GMS, Espinoza GMG, Muñoz RJA

Language: Spanish
References: 14
Page: 13-18
PDF size: 128.65 Kb.

ABSTRACT

An experimental protocol is under study in the Western Medical Center, which consists of trying to protect the reproduction function in patients who have undergone orchiectomy due to testicular cancer and who are subject to radiotherapy and/or chemotherapy. Patients with diagnosis of germinal tumor in stage A subject to chemotherapy or adjuvant radiotherapy were included. It is intended to protect the spermatogonium which shows a vigorous mitosis index of the cytotoxic action of the adjuvant therapy bringing the spermatogonium to a zero stage of cellular reproduction by means of a total androgenic blocking through a gonadotropic inhibitor and an antiandrogen, during the anticancer therapy. The results are assessed by means of the spermatic count in spermatobioscopies, prior and after the treatment. We currently have an experimental group consisting of 6 patients with total androgenic blocking and a control group consisting of 5 patients. The study, still in the experimental stage, has partial results with certain favorable trend towards the protection of the reproduction function, nevertheless we still do not have the total samples to perform a definite analysis. A preliminary report of the progress is presented.

REFERENCES

1. Drasga RE, Einhorn LH, Williams SD, Patel DN. Fertility after chemoterapy for testicular cancer. J Clin Oncol 1983; 1: 179-183.

2. Johnson DH, Hainsworth JD, Linde RB, Greco FA. Testicular function following combination chemotherapy with cisplatin, vinblastine and bleomycin. Med Pediatr Oncol 1984; 12: 233-238.

3. Bredael JJ, Yugrin D, Whitmore WF. Recurrences in surgical stage I nonseminomatous germ cells tumor of the testis. J Urol 1983; 130: 476.

4. Berthelsen JG, Skakkebaek NE. Gonadal function in men with testicular cancer. Fertil Steril 1983; 39: 68-75.

5. Chapman RM. Gonadal injury resulting from chemotherapy. Am J Ind Med 1983; 4: 149-161.

6. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981; 1: 1132-34.

7. Word JA, Robinson J, Furr BJ, Shalet SM. Protection of spermatogenesis in rats from the citotoxic procarbazine by the depot formulation of zoladex, a gonadotropin-releasing hormone agonist. Cancer Res 1988; 50: 568-574.

8. Schally AV, Paz-Bouza JI, Korashima T, Gandle B, Sampson M. Partial prevention of procarbazine induced germinal cell aplasia in rats by sequential GnRH antagonist and testosterone administration. Cancer Res 1988; 48: 4354-4360.

9. Delic JI, Harwood JR, Stanley JA. Time dependence for the protective effect of androgen from procarbazine, induced damage to rat spermatogenesis. Cancer Research 1987; 47: 1344-47.

10. Ward JA, Robinson J, Furr BJA, Shalet SM, Morris IA. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of zoladex. Cancer Res 1990; 50: 568-74.

11. Brennemann W, Brensing KA, Leipner N, Boldt I. Attempeted protection of spermatogenesis from irradiation in patients with seminoma by a GnRH antagonist. Clin Investig 1994; 72: 838-842.

12. Ward JA, Furr BJA, Valcaccin B, Curry B, Bardin CW. Prolonged suppression of rats testis function by a depot formulation of zoladex, a GnRH agonist. J Androl 1989; 10: 478-486.

13. Marko K, Gene W, Ilpo H, Marvin L. Rapid protection of spermatogenesis stem cells against procarbazine by treatment with GnRH antagonist an antiandrogen. Endocrinology 1995; 136: 2881-88.

14. Marko K, Kimberly D, Elizabeth P et al. Suppression of mouse spermatogenesis by a gonadotropin-releasing hormone antagonist and antiandrogen. Endocrinology 1996; 137: 949-955.